Cardiac allograft vasculopathy in heart transplant recipients from hepatitis C viremic donors.
Bernard S KadoshAntoinette S BirsErin FlatteryMaxine StachelKimberly N HongYuhe XiaClaudia G GideaSaima AslamLouai RazzoukTajinderpal SaraonRandal GoldbergShaline RaoVictor PretoriusNader MoazamiDeane E SmithEric D AdlerAlex ReyentovichPublished in: Clinical transplantation (2024)
Our data show that NAT+ donors conferred no increased risk for early CAV or subclinical IVUS disease following transplantation in a cohort of heart transplant patients who were treated for HCV, suggesting the short-term safety of this strategy to maximize the pool of available donor hearts.